Company: SHPH
Filing Date: 2025-01-15
Form Type: S-1
Source: 0001493152-25-002253
Chunk: 161

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-01-15
Form: S-1
Chunk 161
---
 indemnify an officer, director, or former officer or director, to the full extent permitted by law.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

| 101 |

<div align='center'>SHUTTLE PHARMACEUTICALS HOLDINGS, INC.

Consolidated Financial Statements

Contents</div>

| Condensed                                                                                                                   
 Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 (unaudited)                                      
 Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2024 and 2023 (unaudited) | Page 
 F-2  
 F-3  |
|:----------------------------------------------------------------------------------------------------------------------------|:-----|
| Condensed                                                                                                                   
 Consolidated Statements of Changes in Stockholders’ Equity (Deficit) for the three and nine months ended September 30,      
 2024 and 2023 (unaudited)                                                                                                   | F-4  |
| Condensed                                                                                                                   
 Consolidated Statements of Cash Flows for the three and nine months ended September 30, 2024 and 2023 (unaudited)           | F-5  |
| Notes                                                                                                                       
 to Condensed Consolidated Financial Statements (unaudited)                                                                  | F-6  |

| Report                                                                                       
 of Independent Registered Public Accounting Firm, Forvis Mazars LLP (PCAOB ID 686)           
 Consolidated                                                                                 
 Balance Sheets as of December 31 2023 and 2022                                               
 Consolidated                                                                                 
 Statements of Operations for the Years Ended December 31, 2023 and 2022                      | Page 
 F-21 
 F-22 
 F-23 |
|:---------------------------------------------------------------------------------------------|:-----|
| Consolidated                                                                                 
 Statements of Changes in Stockholders’ Equity for the Years Ended December 31, 2023 and 2022 | F-24 |
| Consolidated                                                                                 
 Statements of Cash Flows for the Years Ended December 31, 2023 and 2022                      | F-25 |
| Notes                                                                                        
 to Consolidated Financial Statements                                                         | F-26 |

| F-1 |

<div align='center'>Shuttle Pharmaceuticals Holdings, Inc.